undamentalytics Newsletter
Sign in

SBC Medical Group Holdings Inc (SBC) stock

Add to watchlist

Add holding +

NASDAQ: SBC Nasdaq Health Care Services Next results ~November 13, 2026

B+ Fundamentals grade

SBC Medical Group Holdings Inc is a US-listed company in the health care services industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

~$4.5

Cash-flow model

Base case. Range ~$3.7–$5.5 across our lower- and higher-growth cases (-3%–7% a year).

Price vs value

Modestly overvalued

The price is inside our value range, 19% above our base value.

Price used: $5.31, November 2, 2026

SBC Medical Group Holdings Inc valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders0 buying, 1 selling0 purchases and 3 sales by directors and officers, last 12 monthsInsider trades

Value diary

Our note on each quarter SBC Medical Group files

Where SBC Medical stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $175m, down 6.9% on a year earlier, a smaller fall than the 14.4% decline a quarter earlier. That puts it 30 of 34 for growth among the health care services companies we cover. Free-cash-flow margin rose to 35.3% from -5.5% a year earlier. Operating margin widened to 37.3% from 30.5%. Against its peers on growth, profitability, cash generation and balance sheet, it grades B+. It passes 6 of our 6 financial-health checks. Our cash-flow model value is $4.14 a share, against a share price of $5.75.

Source: 10-Q filed August 13, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 13, 2026 (estimated)

SBC Medical Group Holdings Inc's trailing-twelve-month revenue fell 6.9% year on year, with a free-cash-flow margin of 35.3%. Where it stands out: operating margin of 37.3% ranks 1 of 40 health care services companies we cover. Where it lags: revenue growth of -6.9% ranks 35 of 41 health care services companies we cover.

Our discounted-cash-flow model values the business at ~$4.5 per share in the base case (~$3.7–$5.5 across growth scenarios) — model values under stated assumptions, not a price target.

Current signal Revenue growth accelerating: TTM revenue growth rose to -6.9% (+7.5pp vs the prior quarter).

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • High operating margin. 37.3% of revenue is left as operating profit, against a median of 2.6% for health care services companies we cover.
  • Margins widening. Operating margin is up 6.9 points on a year ago.
  • Strong cash generation. 35.3% of revenue turned into free cash flow, against a median of 5.1% for health care services companies we cover.
  • Net cash. Cash exceeds long-term debt by $0.1bn.
  • Estimates rising. Analysts' consensus for next year's earnings per share has risen 11.3% over 90 days.

Things to watch

  • Results due soon. Results are expected around 13 November; the share price can move sharply on the day.
  • Revenue shrinking. Revenue fell 6.9% over the last 12 months.
  • Volatile shares. Over the past year the shares showed annualised volatility of 56% and a beta of 0.8 against the S&P 500.
  • Insiders selling. 1 insiders sold $20M of stock over the past 365 days and none bought (0% under pre-set trading plans).
  • Gross margin slipping. Gross margin is down 5.1 points on a year ago.

Latest results: FY2026 Q2

Filed August 13, 2026
Earnings per share
$0.10 against an average estimate of $0.12: missed by 14.9%
Revenue
$49m, up 13.4% on a year earlier
Share reaction
+14.4% in the first session after the results on August 13, 2026, against +0.5% for the S&P 500
Next report
November 13, 2026; average EPS estimate $0.12

SBC Medical Group's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+0.7%
  • 1 week-1.1%
  • 1 month+4.3%
  • This year+23.2%
  • 1 year+62.9%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$175M
Operating margin
37.3%
Net margin
28.0%
EPS (TTM, diluted)
$0.48

Growth

Revenue growth
−6.9%
Change in growth rate
+7.5 pts
Share count change
+1.4%

Cash

Free cash flow (TTM)
$61.8M
FCF margin
35.3%

Earnings

Last results
August 13, 2026
Next results (est.)
November 13, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Results
  2. Shareholder vote

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

SBC Medical Group Holdings Inc valuation models and calculator

What the price is pricing in

The share price implies about 7.7% a year of cash-flow growth for five years.

Read with care: free cash flow has swung sharply in the past year (often a one-off tax, legal or working-capital item), so the cash-flow base behind this reading may be unusually low or high.

  • Priced in7.7%
  • Last 12 months-6.9%

Our cash-flow model with every input fixed except growth over the next five years, solved for the growth at which the model value equals the share price ($5.25, Nov 3, 2026). Cash-flow growth then fades to 2.5% a year; discount rate 8.5%. Delivered figures are revenue growth from SEC filings. This is a model exercise, not investment advice or a forecast of the share price. All companies

Fundamentalytics rating

model v1.6 · 2026-11-03
Sell12-month view
12-month price target
~$4.5
Price used
$5.25close November 3, 2026
Implied change
▼ 15%
Uncertainty
Low

How we got here: a discounted-cash-flow model of SBC Medical Group Holdings Inc's free cash flow after stock-based pay with after-tax interest added back ($17.7M, FY2026 Q2 TTM), growing 9.9% and 3.6% in the next two years (forecasts, guidance and its record), then back to 2% by year five, and fading to 2.5%, discounted at 8.5%. Lower and higher growth cases span ~$3.7–~$5.5 ; that spread sets a 15% margin before we rate Buy or Sell.

Produced by Fundamentalytics' automated valuation model on November 3, 2026, using delayed market prices. Rating meanings, methodology and conflicts: recommendations disclosure and research disclaimer. General research, not personal advice — it does not consider your circumstances. Prices can fall as well as rise.

Our value per share comes from a discounted-cash-flow model of SBC Medical Group Holdings Inc's free cash flow after stock-based pay ( $17.7M, FY2026 Q2 TTM, with after-tax interest added back): growth for five years as below (the first two years from forecasts, guidance and the company's record), fading to 2.5%, discounted at 8.5%, then cash added and debt and other claims subtracted. These are model values under stated assumptions, not price targets or recommendations.

Valuation models

We value SBC Medical Group Holdings Inc as an operating company, with every model that fits that kind of business. Cost of equity 8.5%: the 10-year Treasury yield (4.9%) plus a beta of 0.8 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Cash-flow model (DCF) Free cash flow to the firm (after stock pay, with after-tax interest added back), grown then faded to 2.5%, discounted at 8.5% as the firm rate, less debt and other claims. ~$4.5 ~$3.7–$5.5 Primary model, counts double
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. ~$12 ~$11–$17 Included
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: return on equity above 40%: buybacks or intangibles make book value too small an anchor
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. ~$6.3 ~$5.3–$7.6 Included
Combined value Weighted average of the models that apply: the primary model (cash-flow model (dcf)) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$6.7 ~$4.5–$12 3 models

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare SBC Medical Group Holdings Inc with Health Care Services in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

What moves the value

  • Revenue growth 5 points lower ▼ −22%
  • Revenue growth 5 points higher ▲ +29%
  • Free-cash-flow margin 1 point lower ▼ −3%
  • Discount rate 1 point higher ▼ −13%
Value per share under different assumptions
Discount rate ↓ / growth → −5% growth0% growth5% growth10% growth15% growth20% growth
7% $4$5$6$7$9$12
8.5% $3$4$5$6$7$9
10% $3$3$4$5$6$7

Valuation multiples over time Market data may be delayed

At fiscal year end 202320242025Now
Share price$10.77$5.56$4.31$5.31
Market value$1.0bn$537m$444m$545m
+ Net debt (− = net cash)−$87m−$118m−$121m−$147m
Enterprise value$928m$418m$323m$398m
Multiples
Price / sales 5.2x2.6x2.6x3.1x
Price / earnings 25.8x11.5x8.7x11.1x
Price / free cash flow 24.1x29.8x19.1x8.8x
EV / EBITDA 11.2x5.6x4.6x5.9x

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 13, 2026, before the open. Analysts expect revenue of $49m and EPS of $0.12 (range $0.10 to $0.13) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current $0.46 −8% $191m +10%
Next $0.54 +17% $210m +10%

Next year's EPS estimate has moved +11.3% in 90 days, across 2 analysts.

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −1.1% on 90 days ago. In the last 30 days, 2 analysts raised SBC Medical Group Holdings Inc's forecast and 2 cut it.

Consensus EPS forecast SBC Medical Group Holdings Inc, last 90 days
$0.45 $0.50 $0.55 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: $0.47 Current fiscal year, 60 days ago: $0.47 Current fiscal year, 30 days ago: $0.46 Current fiscal year, 7 days ago: $0.46 Current fiscal year, Now: $0.46 $0.46 Next fiscal year, 90 days ago: $0.48 Next fiscal year, 60 days ago: $0.48 Next fiscal year, 30 days ago: $0.54 Next fiscal year, 7 days ago: $0.54 Next fiscal year, Now: $0.54 $0.54

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago $0.47$0.48
60 days ago $0.47$0.48
30 days ago $0.46$0.54
7 days ago $0.46$0.54
Now $0.46$0.54

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 $0.12 $0.10 −14.9%
Mar 2026 $0.10 $0.11 +12.8%
Dec 2025 $0.12 $0.14 +16.7%
Sept 2025 $0.11 $0.12 +5.9%

Adjusted EPS as companies report it, against the average analyst estimate.

How our valuation uses these forecasts

Our cash-flow model grows SBC Medical Group Holdings Inc's revenue by +9.9% next year and +3.6% the year after, then fades back toward its own record by year five. Next year's rate weighs analysts' consensus (+14.6%, weight 62%) and the company's own record (+2.0%, weight 38%) . How the weights are set.

Analyst recommendations

3 analysts, Oct 2026
Buy3100%
Hold00%
Sell00%

Monthly trend

  1. Oct 2026123
  2. Sep 2026123
  3. Aug 2026123
  4. Jul 2026123

Counts of recommendations published by analysts covering SBC Medical Group Holdings Inc, by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
4.0%
of tradable shares
Days to cover
3.46
at average volume
Short interest, 1 month
+5%
to October 15, 2026
Held by institutions
4%
of shares
Held by insiders
81.5%
of shares
Employees
863
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months +62.9%

$3.26 on October 31, 2025 to $5.31

ThenNowEffect
Revenue (last 12 months) $188m $175m −6.9%
Net margin 17.7% 28.0% +58.0%
P/E multiple 9.9x 11.1x +12.3%
Share count 101m 103m −1.4%

Biggest factor: net margin.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 2023202420252026 to date
Return
SBC+6%−48%−23%+23%
Industry peers (median)+8%−6%−6%+15%
S&P 500+26%+25%+18%+11%
Months that ended higher
SBC75%58%33%55%
S&P 50067%75%75%46%
Largest fall from a high during the year
SBC−3%−66%−48%−42%
S&P 500−10%−8%−19%−9%

Worst fall since September 26, 2022: 82% from August 12, 2024 to May 18, 2026. Getting back needed a 458% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$2.87 – $5.69
From 52-week high
−6.7%
vs 50-day average
+8.5%
vs 200-day average
+35.7%
Volatility (1 year)
56%
Beta vs S&P 500
0.82

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
3 up, 5 down
typical move ±8.4%
After a week
3 up, 5 down
typical move ±11.1%
After a month
3 up, 5 down
typical move ±18.2%
Results releasedNext dayS&P 500 next day5 days21 days
August 13, 2026 +14.4% +0.5% +15.0% +41.9%
May 14, 2026 −8.0% −0.4% −4.0% −9.9%
March 27, 2026 +7.6% −2.0% +19.2% −11.1%
November 14, 2025 −9.7% −0.9% −1.5% +22.0%
August 13, 2025 −10.6% +0.4% −12.1% −1.3%
May 15, 2025 +1.2% +1.1% +14.3% +32.1%
March 28, 2025 −14.9% −1.4% −12.3% −10.7%
November 13, 2024 −1.0% −0.6% −10.6% −16.8%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Options strategies

All options ideas

How SBC Medical Group Holdings Inc’s listed options are priced, and three ways to use them that follow from our valuation. Quotes are delayed. Check the live chain at your broker before trading.

Option prices are read during US trading hours (9:30 to 16:00 New York time). Outside them the chain shows no bids or offers, so this screen fills in after the next session opens.

General research, not personal advice. Options can lose you more than you expect and are not suitable for everyone: put sellers can be made to buy shares that keep falling, call sellers give up gains above the strike, and results or news can move prices sharply. Chances shown are approximations from each option’s delta. Spreads, fees and early assignment are not modelled.

SBC Medical Group Holdings Inc in five measures

Fundamentals grade B+
Growth Profitability Cash Balance sheet Value

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) SBC Medical Group Holdings Inc
$160M $180M $200M $220M $240M FY24 Q2 FY24 Q4 FY25 Q2 FY25 Q4 FY26 Q2 Revenue (TTM), FY24 Q2: $217.5M Revenue (TTM), FY24 Q3: $223.3M Revenue (TTM), FY24 Q4: $205.4M Revenue (TTM), FY25 Q1: $197.9M Revenue (TTM), FY25 Q2: $188.2M Revenue (TTM), FY25 Q3: $178.5M Revenue (TTM), FY25 Q4: $173.6M Revenue (TTM), FY26 Q1: $169.3M Revenue (TTM), FY26 Q2: $175.2M $175.2M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY24 Q2 $217.5M
FY24 Q3 $223.3M
FY24 Q4 $205.4M
FY25 Q1 $197.9M
FY25 Q2 $188.2M
FY25 Q3 $178.5M
FY25 Q4 $173.6M
FY26 Q1 $169.3M
FY26 Q2 $175.2M
Revenue growth, TTM YoY SBC Medical Group Holdings Inc
-30% -20% -10% 0% FY25 Q2 FY25 Q3 FY25 Q4 FY26 Q1 FY26 Q2 Revenue growth, TTM YoY, FY25 Q2: -13.5% Revenue growth, TTM YoY, FY25 Q3: -20.1% Revenue growth, TTM YoY, FY25 Q4: -15.5% Revenue growth, TTM YoY, FY26 Q1: -14.4% Revenue growth, TTM YoY, FY26 Q2: -6.9% -6.9%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY25 Q2 -13.5%
FY25 Q3 -20.1%
FY25 Q4 -15.5%
FY26 Q1 -14.4%
FY26 Q2 -6.9%
Operating margin (TTM) SBC Medical Group Holdings Inc
30% 35% 40% 45% FY24 Q2 FY24 Q4 FY25 Q2 FY25 Q4 FY26 Q2 Operating margin (TTM), FY24 Q2: 44.0% Operating margin (TTM), FY24 Q3: 40.1% Operating margin (TTM), FY24 Q4: 34.2% Operating margin (TTM), FY25 Q1: 35.4% Operating margin (TTM), FY25 Q2: 30.5% Operating margin (TTM), FY25 Q3: 33.3% Operating margin (TTM), FY25 Q4: 38.9% Operating margin (TTM), FY26 Q1: 36.0% Operating margin (TTM), FY26 Q2: 37.3% 37.3%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY24 Q2 44.0%
FY24 Q3 40.1%
FY24 Q4 34.2%
FY25 Q1 35.4%
FY25 Q2 30.5%
FY25 Q3 33.3%
FY25 Q4 38.9%
FY26 Q1 36.0%
FY26 Q2 37.3%
FCF margin (TTM) SBC Medical Group Holdings Inc
-40% -20% 0% 20% 40% FY24 Q3 FY25 Q1 FY25 Q3 FY26 Q2 FCF margin (TTM), FY24 Q3: 21.3% FCF margin (TTM), FY24 Q4: 8.8% FCF margin (TTM), FY25 Q1: 8.4% FCF margin (TTM), FY25 Q2: -5.5% FCF margin (TTM), FY25 Q3: -20.1% FCF margin (TTM), FY25 Q4: 13.4% FCF margin (TTM), FY26 Q1: 18.1% FCF margin (TTM), FY26 Q2: 35.3% 35.3%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY24 Q3 21.3%
FY24 Q4 8.8%
FY25 Q1 8.4%
FY25 Q2 -5.5%
FY25 Q3 -20.1%
FY25 Q4 13.4%
FY26 Q1 18.1%
FY26 Q2 35.3%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-K/A, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Where the money goes

FY2025, from the 10-K

Each dollar SBC Medical Group took in during FY2025, followed through to profit: what it cost to make, what went on running the business, and what was left after tax.

  1. Revenue $174M
  2. Other income $14.5M · 8.4%
  3. Cost of revenue $46.3M · 26.7%
  4. Gross profit $127M · 73.3%
  5. Selling, general and admin $59.8M · 34.4%
  6. Operating income $67.5M · 38.9%
  7. Income tax $31M · 17.9%
  8. Net income $51M · 29.4%

Shares of revenue. Source: SBC Medical Group's 10-K for FY2025, as filed with the SEC. Other income is income outside operations, such as investment gains.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 194 205 174 175
Gross profit 137 156 127 126
EBITDA 83 74 70 68
Operating income 71 70 67 65
Net income 39 47 51 49
Diluted EPS $0.42 $0.48 $0.50 $0.48
Growth (year on year)
Revenue — +6.1% −15.5% −6.9%
EBITDA — −10.6% −5.3% +12.4%
Operating income — −0.5% −4.0% +14.1%
Net income — +18.4% +9.4% +47.1%
Diluted EPS — +14.3% +4.2% +45.0%
Margins
Gross margin 70.9% 76.0% 73.3% 71.9%
EBITDA margin 42.8% 36.1% 40.4% 38.6%
Operating margin 36.5% 34.2% 38.9% 37.3%
Net margin 20.3% 22.7% 29.4% 28.0%
Free-cash-flow margin 21.8% 8.8% 13.4% 35.3%
Cash flow
Cash from operations 51 21 25 63
Capital spending 9 3 1 1
Free cash flow 42 18 23 62
Stock-based pay — 13 0 —
Free cash flow after stock pay — 5 23 —
Balance sheet
Cash 103 125 164 184
Total debt 16 7 43 38
Net debt (negative = net cash) −87 −118 −121 −147
Diluted shares 94m 97m 103m 103m
Returned to shareholders
Buybacks — 0 5 —
Total returned — 0 5 —

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

6 of 6 checks passed · June 30, 2026
What it owns · $407m
Short-term assets $259mLonger-term assets $147m
What it owes, and who funded it · $391m
Short-term liabilities $78mLonger-term liabilities $48mShareholders' equity $264m
  • Short-term assets cover short-term liabilities $259m of assets due within a year against $78m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $259m short-term assets against $48m of longer-dated liabilities.
  • More cash than debt $184m of cash against $38m of debt.
  • Debt below 40% of shareholders' equity Debt is 14% of equity.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt $63m of operating cash flow against $38m of debt.
  • Operating profit covers interest at least five times over Operating income of $65m against $335,571 of interest.

From SBC Medical Group Holdings Inc's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+1.4%
year over year
Sales & admin spending
34.5%
of revenue

Competitors: side by side with peers

Closest by revenue in health care services
Last 12 months unless stated SBC PETS AIRS NRC RDGT DLHC Median
Revenue, last 12 months $175m $169m $151m $140m $132m $254m $1.2bn
Revenue growth, last 12 months −6.9% −20.3% −8.7% −0.2% 10.2% −29.5% 7.3%
Revenue growth, 3-year average — −13.0% −5.9% −1.9% — −9.5% 11.3%
Revenue growth, latest quarter 13.4% −19.9% −2.5% 4.0% — −46.9% 8.5%
Gross margin 71.9% 27.9% — — 3.6% 24.3% 27.9%
Operating margin 37.3% −18.2% −8.4% 10.5% −1.4% −0.1% 2.3%
Operating margin, 3-year average 37.3% −12.6% −3.0% 19.1% — 3.5% 2.3%
Net margin 28.0% −17.3% −7.8% 4.0% −0.9% −8.5% 1.2%
Cash from operations / revenue 35.9% −14.1% 0.8% 21.1% −1.1% 5.5% 6.1%
Free-cash-flow margin 35.3% −16.4% 0.5% 15.5% −1.1% 5.5% 5.1%
Free-cash-flow margin, 3-year average — −7.3% 0.6% 12.5% — 6.6% 3.6%
Stock pay / revenue — 0.6% 0.8% 8.4% 8.6% 0.5% 1.1%
Change in share count 1.4% 2.9% 13.3% −5.2% 96.6% 2.2% 0.3%

Median of all 41 companies we cover in health care services. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

41 health care services companies
Measure Company Peer median Rank
Revenue growth Growth -6.9% 7.3% 35 of 41
Change in growth rate Growth +7.5pp +1.1pp 5 of 41
Gross margin Profitability 71.9% 29.0% 2 of 27
Operating margin Profitability 37.3% 2.6% 1 of 40
Net margin Profitability 28.0% 1.2% 1 of 41
Free-cash-flow margin Cash generation 35.3% 5.1% 2 of 40
Long-term debt as % of assets Balance sheet 9.3% 27.7% 7 of 31
Change in share count Balance sheet 1.4% 0.4% 23 of 39

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
Procurement Services $56.1M 32.3% ▲ 2.3%
Franchising $45.9M 26.5% ▼ 24.7%
Management Services $29.6M 17.1% ▼ 44.2%
Rental Services $23M 13.3% ▲ 42.7%
Other $18.9M 10.9% ▼ 6.7%

From SBC Medical Group Holdings Inc's 10-K filed March 27, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

13F filings for June 30, 2026
Reported value
$13.5M
Institutions reporting
57
Shares held vs prior quarter
▲ 202.8%
Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Lumbard & Kellner, LLC $5.3M 1.7M 39.3% ▲ 9899.5%
Blackrock, Inc. $2.8M 924K 21.0% ▲ 120.2%
Geode Capital Management, LLC $1.3M 428K 9.7% ▲ 44.7%
Citadel Advisors LLC $445,731 145K 3.3% New
Vanguard Capital Management LLC $418,212 136K 3.1% ▼ 0.3%
Northern Trust Corp $404,108 131K 3.0% ▲ 44.0%
Vanguard Portfolio Management LLC $395,149 128K 2.9% ▲ 101.9%
Hillsdale Investment Management Inc. $384,384 125K 2.8% New
Segall Bryant & Hamill, LLC $250,426 81K 1.8% 0.0%
Vanguard Fiduciary Trust Co $204,145 66K 1.5% ▲ 6.1%
Sbi Securities Co., Ltd. $152,266 49K 1.1% ▲ 9.7%
State Street Corp $151,656 49K 1.1% ▲ 59.7%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not SBC Medical Group Holdings Inc's complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $20.1M 3 trades by 1 insider · 0% under pre-set plans
Net ▼ $20.1M net selling
Insider Date Trade Shares Price Value
Aikawa Yoshiyuki Chairman and CEO April 28, 2026 Sell 465,000 $3.02 $1.4M
Aikawa Yoshiyuki Chairman and CEO April 21, 2026 Sell 3,100,000 $3.02 $9.4M
Aikawa Yoshiyuki Chairman and CEO March 6, 2026 Sell 4,422,900 $2.12 $9.4M

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around November 13, 2026 estimated from the company's past filing pattern, not announced

  • August 13, 2026
  • May 14, 2026
  • March 27, 2026
  • November 14, 2025
  • August 13, 2025
  • May 15, 2025

Recent SEC filings

Data status

When each part of this page on SBC Medical Group Holdings Inc was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

SBC Medical Group Holdings Inc in brief

What does SBC Medical Group Holdings Inc do?
SBC Medical Group Holdings Inc is a US-listed company in the health care services industry. Its financial year ends in December.
What is SBC Medical Group Holdings Inc's stock ticker?
SBC Medical Group Holdings Inc trades under the ticker SBC on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is SBC Medical Group Holdings Inc's revenue, and how fast is it growing?
Over its most recent trailing twelve months, SBC Medical Group Holdings Inc reported revenue of $175M, 6.9% lower than a year earlier, according to its SEC filings.
What is SBC Medical Group Holdings Inc's free cash flow?
SBC Medical Group Holdings Inc's free-cash-flow margin is 35.3% of revenue over the trailing twelve months, ranking 2 of the 40 health care services companies we cover.
What is SBC Medical Group Holdings Inc's fair value (intrinsic value) per share?
Our discounted-cash-flow model of SBC Medical Group Holdings Inc's free cash flow after stock-based pay gives ~$4.5 per share in the base case, and ~$3.7–$5.5 across growth scenarios. These are model values under stated assumptions — not a price target or a recommendation.
Who are SBC Medical Group Holdings Inc's largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Lumbard & Kellner, LLC, Blackrock, Inc. and Geode Capital Management, LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is SBC Medical Group Holdings Inc's market cap?
On November 2, 2026, SBC Medical Group Holdings Inc's market capitalisation was about $545M, with a price-to-earnings ratio of 11.1 and net debt of -$147M. Market figures come from third-party market data and may be delayed.
How much debt does SBC Medical Group Holdings Inc have?
SBC Medical Group Holdings Inc's debt-to-equity ratio is 14.4%, from its latest balance sheet. The financial health section below sets out its other solvency checks.
Who are SBC Medical Group Holdings Inc's competitors?
In our Health Care Services peer group, the companies closest to SBC Medical Group Holdings Inc are Petmed Express Inc, Airsculpt Technologies, Inc., NRC Health, Ridgetech Inc. and DLH Holdings Corp. The side-by-side comparison below sets their revenue, margins and growth against SBC Medical Group Holdings Inc's.
Are insiders buying or selling SBC Medical Group Holdings Inc stock?
Over the last 12 months, SBC Medical Group Holdings Inc's directors and officers reported 0 open-market purchases and 3 sales on Form 4. The insider trading page charts every trade.
When is SBC Medical Group Holdings Inc's next earnings date?
Around November 13, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — SBC Medical Group Holdings Inc announces its own schedule.